Sign up to save your podcasts
Or
Share Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.
View all episodes
By BiotechTV
4.3
66 ratings
She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.
More shows like BiotechTV - News
View all
We Study Billionaires - The Investor’s Podcast Network
3,374 Listeners
Bloomberg Businessweek
426 Listeners
WSJ Tech News Briefing
1,644 Listeners
The Meb Faber Show - Better Investing
938 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Readout Loud
321 Listeners
Value Investing with Legends
213 Listeners
Fiction - Comedy Fiction
6,444 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,907 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
5 Listeners
Cheeky Pint
49 Listeners